Ardelyx (NASDAQ:ARDX) Now Covered by Analysts at TD Cowen

Investment analysts at TD Cowen began coverage on shares of Ardelyx (NASDAQ:ARDX) in a research report issued to clients and investors on Wednesday, Zacks reports. The firm set a “strong-buy” rating on the biopharmaceutical company’s stock.

ARDX has been the subject of several other research reports. BTIG Research cut their price objective on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Citigroup decreased their target price on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wedbush reissued an “outperform” rating and issued a $9.00 target price on shares of Ardelyx in a report on Tuesday, August 18th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a research report on Friday, August 7th. Finally, Zacks Research raised shares of Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.90.

Ardelyx Price Performance

Shares of NASDAQ ARDX opened at $2.99 on Wednesday. The business has a fifty day moving average price of $3.37 and a two-hundred day moving average price of $5.26. The stock has a market capitalization of $751.60 million, a PE ratio of -13.59 and a beta of 0.79. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15. Ardelyx has a fifty-two week low of $2.95 and a fifty-two week high of $8.40.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.30% and a negative net margin of 11.85%. The company had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. During the same period last year, the company posted ($0.08) earnings per share. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, equities analysts predict that Ardelyx will post -0.20 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael Raab sold 58,574 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the transaction, the chief executive officer owned 1,619,792 shares of the company’s stock, valued at approximately $6,252,397.12. The trade was a 3.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laura Williams sold 10,739 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $41,452.54. Following the sale, the insider owned 367,456 shares of the company’s stock, valued at approximately $1,418,380.16. This represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 126,059 shares of company stock worth $486,588. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. CenterBook Partners LP increased its holdings in shares of Ardelyx by 29.0% during the third quarter. CenterBook Partners LP now owns 60,140 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 13,536 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Ardelyx in the third quarter valued at about $39,000. Chicago Partners Investment Group LLC raised its position in Ardelyx by 33.8% in the third quarter. Chicago Partners Investment Group LLC now owns 57,655 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 14,563 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ardelyx during the third quarter valued at about $44,000. Finally, Profund Advisors LLC boosted its stake in shares of Ardelyx by 6.1% during the third quarter. Profund Advisors LLC now owns 111,771 shares of the biopharmaceutical company’s stock valued at $382,000 after purchasing an additional 6,433 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Ardelyx reported third-quarter EPS of $0.00, ahead of analysts’ expectation of a $0.02 loss. Product revenue was $125.5 million, while total revenue of $127.66 million came in slightly below estimates; revenue grew 21% year over year. The company maintained its 2026 IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 earnings
• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.04 from $0.01 and its FY2026 estimate to a loss of $0.18 per share from a loss of $0.26. The firm kept its Buy rating and $13 price target. TD Cowen also reaffirmed its Buy rating. TD Cowen rating
• Neutral Sentiment: The company completed enrollment in its Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, an operational milestone ahead of future trial updates. ACCEL trial enrollment
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027, FY2029 and FY2030, including a reduction for FY2029 to $1.18 from $1.56. The longer-term estimate revisions temper the improvement in its near-term outlook.
• Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx, with a November 16 lead-plaintiff deadline. The lawsuit alleges the company misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these claims are allegations, not established findings. Litigation adds uncertainty and reputational risk. Class action allegations

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.